The company yesterday announced that it has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Eptifibatide Injection USP, 20 mg/10 mL, 75 mg/100 mL, and 200 mg/100 mL single-use vials.
| Subscribe To Our Free Newsletter |
